<DOC>
	<DOCNO>NCT00941278</DOCNO>
	<brief_summary>PH-10 aqueous hydrogel formulation rise bengal disodium ( RB ) topical administration skin , study treatment cutaneous skin disorder , specifically psoriasis atopic dermatitis . This phase 2 efficacy safety study assess topical PH-10 apply daily area mild moderate plaque psoriasis .</brief_summary>
	<brief_title>An Efficacy Safety Study PH-10 Aqueous Hydrogel Treatment Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Men woman , age 18 older . Presence mild moderate plaque psoriasis trunk extremity ( exclude palm , sol , scalp , facial intertriginous area ) . Fitzpatrick skin type IVI . Written inform consent subject legal guardian . Women childbearing potential pregnant , attempt conceive , use effective contraception , nurse infant . Subjects receive PUVA systemic antipsoriatic therapy ( immunosuppressant , cytostatics , corticosteroid ) within 28 day study initiation ( two week methotrexate ) . Subjects received UVB light therapy within 14 day study initiation . Subjects received topical antipsoriatic therapy ( include corticosteroid , tar , anthralin Vitamin D analog ) study plaque area within 14 day study initiation . Subjects received agent pose clinically significant risk photosensitivity reaction within 5 halflives study initiation . Subjects receive approved investigational biologic drug therapy psoriasis within 90 day 5 halflives study initiation . Subjects participate clinical research study within 28 day study initiation . Subjects history porphyria , systemic lupus erythematosus xeroderma pigmentosum . Subjects clinical condition , opinion Investigator may pose health risk subject involve study detrimentally affect regular followup subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>